Trump Executive Order Directs FDA to Fast-Track Psychedelics for Mental Health Crisis

President Trump has bypassed Congress to directly reshape federal drug policy, using an executive order to mandate the rapid expansion of psychedelic drug access for treating serious mental illness. The order, framed as a move to "reverse the crisis," commands federal health agencies to accelerate regulatory pathways and re-evaluate the drugs' controlled substance status, signaling a sharp, top-down shift in the government's approach to psychedelic medicine.

The directive explicitly targets the Food and Drug Administration (FDA), ordering it to expedite the designation of certain psychedelics as "breakthrough" therapies. Crucially, it also leverages Right-to-Try legislation, opening a channel for terminally ill patients to access these experimental treatments outside standard clinical trial protocols. This creates a dual-track system: one for fast-tracked FDA approval and another for immediate, pre-approval patient use under specific, dire circumstances.

The move places immense, immediate pressure on the FDA and the Department of Health and Human Services to reinterpret decades of drug scheduling policy. It risks creating significant tension between the executive branch's public health directives and the agencies' established, science-based review processes. The order's focus on mental illness treatment could rapidly alter the research, investment, and legal landscape for psychedelics like psilocybin and MDMA, pushing them from the fringe of clinical research toward the center of a national public health strategy.